Incorrect password
evipedia.ai Suggest Edit

Ashwagandha for Health & Longevity

Evidence Review created on 04/30/2026 using AI4L / Opus 4.7

Also known as: Withania somnifera, Indian Ginseng, Winter Cherry, Asgandh, Asgand, Aswagandha, Poison Gooseberry

Motivation

Ashwagandha (Withania somnifera) is a small evergreen shrub native to drier regions of India, the Middle East, and parts of Africa, whose root has been used for thousands of years in Ayurvedic medicine as an adaptogen — a class of plants traditionally said to help the body cope with stress. Standardized root extracts are now among the most widely sold botanical supplements globally, primarily marketed for stress, sleep, and physical performance.

Renewed scientific interest has produced dozens of randomized controlled trials over the past two decades, focused largely on stress, sleep, and physical performance. At the same time, post-marketing reports of liver injury and a small number of thyroid-related adverse events have prompted regulatory attention in several countries, while extracts standardized for differing withanolide content (e.g., KSM-66, Sensoril, Shoden) have proliferated.

This evidence review examines the current state of research on Ashwagandha, including its underlying mechanisms, benefits, risks, interactions, and practical protocols, and considers the strength of the evidence underpinning each domain.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources providing accessible overviews of Ashwagandha’s health applications.

  • Ashwagandha root extract boosts stress resistance - Rhonda Patrick

    FoundMyFitness Science Digest entry summarizing a randomized, double-blind, placebo-controlled trial in chronically stressed adults using 300 mg of high-concentration full-spectrum root extract for 60 days, framed by Rhonda Patrick’s adaptogen commentary on heat-shock proteins, neuroprotection, and cortisol-mediated stress physiology.

  • AMA #69: Scrutinizing supplements: creatine, fish oil, vitamin D, and more — a framework for understanding effectiveness, quality, and individual need - Peter Attia

    Peter Attia walks through a personal framework for evaluating supplements and applies it to ashwagandha, including the human evidence on cortisol and sleep quality, his own experience using 600 mg in the evening, contraindications (pregnancy, breast-feeding, pre-surgery, ulcers, autoimmune and thyroid disease), and quality considerations for selecting an extract.

  • Ashwagandha’s Brain Benefits - Rick Wilson

    Life Extension Magazine review of how root and leaf extracts (withaferin A, withanolides, withanosides) cross the blood–brain barrier and engage GABA receptors, with summarized human data on cognition, anxiety, and sleep, plus preclinical work relevant to age-related cognitive decline. (Conflict of interest: Life Extension is a supplement manufacturer that sells ashwagandha products and derives direct revenue from the conclusions promoted in its magazine.)

  • RHR: From Wired & Tired to Calm & Clear: My Top Nutrients for Mood, Focus, and Sleep - Chris Kresser

    Functional-medicine podcast in which Chris Kresser places ashwagandha among five core nutrients for chronic stress and poor sleep, covering its action on cortisol, GABA, and the hypothalamic–pituitary–adrenal axis, branded extract differences (e.g., Shoden), and practical combination strategies. (Conflict of interest: Kresser founded Adapt Naturals, which sells supplements that compete with stand-alone ashwagandha products and benefit from his framing of the category.)

  • Ashwagandha: Is it helpful for stress, anxiety, or sleep? - National Institutes of Health Office of Dietary Supplements

    Health-professional-oriented overview from the NIH Office of Dietary Supplements, covering taxonomy, withanolide content of common extracts (KSM-66, Sensoril, Shoden), human trial findings for stress, anxiety, and sleep, and a structured safety section including hepatotoxicity, thyroid effects, and known interactions.

Note: A dedicated long-form Ashwagandha article from Andrew Huberman (hubermanlab.com) was not located despite searches across his platform; Huberman discusses Ashwagandha repeatedly in podcast Q&A excerpts and the AI knowledge base, but no single dedicated article meets the inclusion criteria. The NIH Office of Dietary Supplements professional fact sheet was therefore included to round out the list with an authoritative non-mainstream-media overview that does not have its own dedicated section in this review.

Grokipedia

Ashwagandha

Grokipedia’s article provides a comprehensive overview of Ashwagandha (Withania somnifera), covering its botany, Ayurvedic history, withanolide chemistry, and modern clinical research on cortisol reduction, anxiety, cognition, exercise recovery, and male reproductive hormones, as well as a discussion of its place among adaptogens relative to Rhodiola rosea.

Examine

Ashwagandha

Examine.com’s evidence-based supplement page summarizes the human research on ashwagandha for stress, anxiety, sleep, cognition, exercise performance, and hormone health, with a graded effect-size matrix, drawbacks discussion, and an annotated literature feed of individual study summaries.

ConsumerLab

Ashwagandha Supplements Review

ConsumerLab’s review covers third-party testing of 13 ashwagandha products (only 5 Approved; 38% pass rate), guidance on choosing root powder vs. extract by withanolide content (≥0.3% for powder, ≥1.5% for extract; ≥6 mg withanolides per daily dose), dosage ranges used in clinical trials, safety considerations including liver injury, and Top Pick recommendations.

Systematic Reviews

A selection of the most relevant systematic reviews and meta-analyses examining Ashwagandha’s effects across stress, sleep, exercise, and overall safety.

Mechanism of Action

Ashwagandha’s pharmacology centers on a family of steroidal lactones called withanolides — most notably withaferin A, withanolide A, withanone, and the withanosides found in higher concentrations in leaves than roots. Standardized commercial extracts target the root and are typically certified to 1.5–10% withanolides, while leaf-containing preparations carry higher withaferin A content.

The most consistently demonstrated effects in human trials center on the hypothalamic–pituitary–adrenal (HPA) axis (the brain-and-adrenal circuit that produces cortisol in response to stress):

  • HPA-axis modulation: Withanolides reduce cortisol secretion in stressed individuals, with meta-analytic evidence of a meaningful drop in serum cortisol over 30–112 days. The proposed mechanism includes dampened hypothalamic CRH (corticotropin-releasing hormone) drive and downregulation of adrenal steroidogenic enzymes.

  • GABAergic activity: Withanolides act as positive allosteric modulators at GABA-A receptors (GABA = gamma-aminobutyric acid, the brain’s main inhibitory neurotransmitter; GABA-A receptors are the same target as benzodiazepines, although ashwagandha’s binding is much weaker), contributing to anxiolytic and sleep-promoting effects without the marked sedation or dependence profile of benzodiazepines.

  • Antioxidant and anti-inflammatory pathways: Withanolides upregulate Nrf2 (a master transcription factor that activates the cell’s antioxidant defenses) and downregulate NF-κB (a transcription factor that drives inflammatory gene expression), reducing markers such as CRP (C-reactive protein, a general marker of systemic inflammation), TNF-α, and IL-6 in some trials.

  • Endocrine effects: In subclinical hypothyroid populations, ashwagandha increases free T3 (triiodothyronine, the most active form of thyroid hormone) and T4 (thyroxine, the storage form of thyroid hormone) and lowers TSH (thyroid-stimulating hormone, the pituitary signal that drives thyroid hormone production); in stressed and infertile men, it modestly raises serum testosterone and improves semen parameters; effects on sex hormones in women are less consistent.

  • Neuroplasticity and neuroprotection (preclinical): Animal and in-vitro work suggests withanolides promote dendrite outgrowth, regenerate axons, and reduce amyloid-β toxicity, but human cognitive trials remain small and heterogeneous.

Competing mechanistic interpretations exist. One view treats ashwagandha primarily as an HPA-axis modulator whose downstream effects (sleep, cognition, testosterone) follow indirectly from cortisol reduction. An alternative emphasizes direct receptor-level actions (GABA-A; NMDA — N-methyl-D-aspartate, a glutamate-receptor subtype involved in learning and memory; AChE — acetylcholinesterase, the enzyme that breaks down the neurotransmitter acetylcholine; androgen receptor engagement) that operate independently of cortisol. The two are not mutually exclusive, and the relative contribution of each likely varies between root-only and leaf-containing extracts.

Ashwagandha is a botanical preparation rather than a single-molecule pharmacological compound, so traditional pharmacokinetic descriptors (half-life, fixed metabolism) apply imperfectly. Withaferin A in animals shows rapid oral absorption with a short plasma half-life of roughly 1–2 hours; withanolides do not appear to be substantial inhibitors of CYP3A4 (a major liver enzyme that metabolizes roughly half of all prescription drugs) or CYP2D6 (a liver enzyme that processes many psychiatric and cardiovascular drugs) at typical doses based on available in-vitro and in-vivo data, although clinical interaction studies are limited.

Historical Context & Evolution

Ashwagandha is described in the Charaka Samhita and other classical Ayurvedic texts (roughly 6th century BCE to 2nd century CE) as a rasayana — a rejuvenating tonic given to support strength, vitality, longevity, and recovery from illness. Its Sanskrit name combines ashva (“horse”) with gandha (“smell”), referring both to the odor of the fresh root and to a folk claim of conferring “the strength of a stallion.” It was traditionally prescribed for general weakness, insomnia, joint pain, infertility, and convalescence, often as a powdered root taken with milk and ghee.

In Unani and South Asian folk medicine, ashwagandha was used in similar tonic roles, and a small parallel tradition developed around its use as a topical for wounds and skin conditions. Western scientific investigation began in earnest in the mid-20th century, with isolation and characterization of withaferin A and other withanolides in the 1960s and 1970s.

The modern shift toward ashwagandha as a health-and-longevity intervention came from three converging streams:

  • Adaptogen pharmacology research (1960s–1990s), originating in Soviet work on stress-resistance plants such as Rhodiola rosea and Eleutherococcus senticosus, which framed ashwagandha as part of a class capable of normalizing physiological responses to stressors.

  • Clinical trial expansion (2000s–present), with progressively larger and better-controlled trials of standardized extracts (notably KSM-66 from 2009 and Sensoril) targeting stress, sleep, exercise, and reproductive parameters in non-clinical and subclinical populations.

  • Direct-to-consumer supplement growth (2015–present), driven by integrative practitioners, longevity-oriented podcasts, and large-scale e-commerce, raising annual market valuation to several hundred million USD globally.

Reception has been mixed. Several human trials originally cited for stress and cognition were small, used proprietary extracts, and were industry-funded, prompting later meta-analyses to flag low certainty of evidence and high heterogeneity rather than to dismiss the findings outright. A small but growing post-2017 case literature on ashwagandha-associated cholestatic liver injury — concentrated in Iceland, the United States, India, and Japan — has prompted regulatory advisories in several jurisdictions, including a 2023 Danish ban on ashwagandha-containing food supplements. Whether the case reports reflect specific extract types, contaminants, host susceptibility (including underlying chronic liver disease), or an intrinsic property of ashwagandha withanolides remains under active investigation rather than settled.

Expected Benefits

Medium 🟩 🟩

Reduction of Stress and Anxiety

Multiple RCTs and meta-analyses in adults with self-reported chronic stress or generalized anxiety show consistent reductions in Perceived Stress Scale (PSS — a 10-item self-report questionnaire measuring how stressful life feels) and Hamilton Anxiety Scale (HAM-A — a clinician-administered scale rating the severity of anxiety symptoms) scores after 6–12 weeks of standardized root extract. The proposed mechanism is HPA-axis modulation with downstream GABAergic activity. Effect sizes are large in pooled analyses (SMD — standardized mean difference, a way of comparing effect sizes across studies — around −1.5 for anxiety in the 2022 Akhgarjand meta-analysis), but heterogeneity is high (I² — a measure of variability between trials — above 90%) and the certainty of evidence has been rated low by independent reviewers because most trials are small, short, and conducted by industry-affiliated groups, including manufacturer-funded studies on proprietary extracts (notably KSM-66 by Ixoreal Biomed and Sensoril by Natreon, whose makers derive direct revenue from positive trial outcomes).

Magnitude: Standardized mean difference approximately −1.5 to −1.75 for stress and anxiety scales versus placebo; mean reduction of roughly 4–5 points on PSS and 2–6 points on HAM-A across pooled trials.

Reduction in Serum Cortisol

In stressed adult populations, ashwagandha root extract lowers morning serum cortisol relative to placebo across most controlled trials reviewed by Della Porta et al. and others. The mechanism is consistent with reduced HPA-axis output and is supported by parallel reductions in subjective stress. Effects in non-stressed, eucortisolemic populations are smaller and less consistent.

Magnitude: Approximate mean cortisol reductions of 15–30% from baseline (mean difference around −2.6 µg/dL in the Arumugam et al. 2024 meta-analysis), with 250–600 mg/day root extract over 8 weeks.

Low 🟩

Improvement in Sleep Quality

Pooled analyses of small RCTs in adults — most prominently in those with diagnosed insomnia — show improvements in subjective sleep quality (Pittsburgh Sleep Quality Index — PSQI, a self-report questionnaire scoring overall sleep quality over the prior month), sleep onset latency, and total sleep time at doses ≥600 mg/day for ≥8 weeks. The proposed mechanism combines GABAergic activity, cortisol reduction at sleep onset, and possibly direct effects on sleep architecture mediated by triethylene glycol identified in ashwagandha leaves. Effect sizes are modest, and benefits in healthy non-insomniac populations are smaller and less consistent.

Magnitude: Standardized mean difference approximately −0.59 for overall sleep quality in the 2021 Cheah meta-analysis; subgroup effects larger in insomniacs at ≥600 mg/day over ≥8 weeks.

Improvement in Aerobic Capacity (VO₂max)

In athletes and active healthy adults, 8–12 weeks of standardized root extract is associated with a small increase in VO₂max in pooled trials. Mechanisms proposed include reduced exercise-induced oxidative stress, improved cardiovascular adaptation, and possibly enhanced erythropoiesis. The number of trials is small, and heterogeneity is high.

Magnitude: Mean difference of approximately +3.0 mL/kg/min in VO₂max in the Pérez-Gómez et al. 2020 meta-analysis, observed across athletic and non-athletic populations.

Modest Improvement in Strength and Recovery

Several RCTs in resistance-trained men report modest gains in 1-rep-max bench press and squat, lean body mass, and reductions in markers of exercise-induced muscle damage (creatine kinase) with 600 mg/day root extract over 8–12 weeks. The proposed mechanisms include reduced cortisol-driven catabolism and modest androgenic effects. The trials are small and predominantly industry-funded.

Magnitude: Reported strength gains roughly 5–15 kg above placebo in 1-rep-max lifts and approximately 1.5–2 kg additional lean mass over 8–12 weeks; cohort sizes are typically 40–60 participants.

Modest Increase in Total Testosterone in Men

Across trials in stressed, overweight, and infertile men, root extract has been associated with small to moderate increases in total serum testosterone. The mechanism is consistent with HPA-axis modulation (lowered cortisol freeing the HPG axis — the hypothalamic-pituitary-gonadal circuit that controls sex-hormone production) and possibly direct effects on testicular steroidogenesis. The 2024 systematic review by Morgado et al. classified ashwagandha as “possibly effective” for raising testosterone in healthy men and men with late-onset hypogonadism. Effects are not observed in women.

Magnitude: Mean increases of roughly 30–80 ng/dL total testosterone in pooled male cohorts; clinically modest relative to a typical eugonadal range of 300–1,000 ng/dL.

Cognitive Performance in Healthy Adults ⚠️ Conflicted

Small RCTs in healthy adults and adults with mild cognitive impairment report improvements in reaction time, sustained attention, working memory, and executive function with 300–600 mg/day root extract over 8–12 weeks. The proposed mechanisms include cholinesterase inhibition, antioxidant activity, and reduced cortisol-driven hippocampal stress. The cognitive evidence base is smaller and less consistent than the stress and sleep evidence.

Magnitude: Improvements of approximately 10–20% on attention and reaction-time tasks versus placebo; effect sizes vary substantially across batteries.

Improvement in Subclinical Hypothyroid Markers

In one well-cited 8-week RCT in adults with subclinical hypothyroidism, 600 mg/day root extract increased serum T3 by approximately 41% and T4 by approximately 19%, and lowered TSH by approximately 17%, relative to placebo. Mechanism appears to involve HPA-axis modulation and direct stimulation of thyroid hormone synthesis. The evidence is limited to small populations and a single primary trial, and the same mechanism creates risk in hyperthyroid individuals (see Risks).

Magnitude: Approximate changes of +41% T3, +19% T4, and −17% TSH in subclinical hypothyroidism at 600 mg/day over 8 weeks.

Speculative 🟨

Neuroprotection and Cognitive Aging

Animal and in-vitro studies show that withanolides cross the blood–brain barrier and promote dendrite outgrowth, neurite regeneration, and reduction of amyloid-β toxicity. Withanamide and withaferin A also demonstrate cholinesterase inhibition relevant to Alzheimer-type pathology. Human trials in mild cognitive impairment are small and short, and no controlled trial in established Alzheimer’s or Parkinson’s disease has shown disease modification. The case for neuroprotection in healthy adults rests almost entirely on mechanistic and animal evidence rather than human longitudinal data.

Modulation of Menopausal Symptoms

A 2021 RCT and a small 2024 study reported reductions in menopause-rating-scale scores, hot flashes, and improvements in serum estradiol with 600 mg/day root extract over 8 weeks. The mechanism is hypothesized to involve HPA modulation and possibly weak estrogenic activity. The number of trials is too small and the populations too narrow to establish a robust effect, and the role versus placebo and lifestyle confounding remains uncertain.

Glycemic and Lipid Modulation

Small trials in adults with type 2 diabetes and dyslipidemia have reported modest reductions in fasting glucose, HbA1c (hemoglobin A1c, a measure of average blood sugar over the prior 2–3 months), LDL (low-density lipoprotein, the cholesterol fraction most associated with cardiovascular risk), and triglycerides, with mechanisms proposed via insulin sensitization, anti-inflammatory action, and HPA modulation. The trials are small, short, and use heterogeneous formulations; ashwagandha is not currently considered an evidence-based intervention for either condition.

General Adaptogen / “Healthspan” Effect

The traditional Ayurvedic framing of ashwagandha as a rasayana maps loosely to a modern adaptogen claim that broad, low-grade improvements across stress, sleep, cognition, immunity, and physical function add up to a healthspan benefit. There are no longevity-relevant clinical endpoints (all-cause mortality, deficit-accumulation frailty, disease-free survival) that have been studied in ashwagandha trials. The basis for this claim is mechanistic, observational, and traditional rather than empirical at the longevity level.

Benefit-Modifying Factors

  • Baseline stress level: Anxiolytic, cortisol-lowering, and sleep effects are most pronounced in adults with elevated baseline perceived stress, anxiety, or insomnia. Effects in non-stressed, well-sleeping adults are smaller and less consistent.

  • Baseline thyroid status: Adults with subclinical hypothyroidism show meaningful T3, T4, and TSH improvements; euthyroid adults show smaller and less consistent thyroid effects, while hyperthyroid individuals are at risk of further T3/T4 elevation rather than benefit (see Risks).

  • Baseline testosterone status: Men with low or low-normal baseline testosterone, infertility, or chronic stress show clearer testosterone increases; eugonadal men show smaller and inconsistent effects.

  • Baseline VO₂max and training status: Both untrained and trained adults show VO₂max increases, but the relative effect appears larger in less-trained populations approaching their physiological ceiling more slowly.

  • Sex differences: Anxiolytic and sleep effects are reported in both sexes. Testosterone-raising effects are essentially confined to men. Limited data exist on female-specific reproductive endpoints aside from menopausal symptoms.

  • Age: Most trials enroll adults aged 18–65, with limited data in adults over 65. Older adults may have greater age-related declines in cortisol regulation and could plausibly experience larger HPA-axis benefits, but they are also at higher baseline risk for the hepatotoxic and thyroid-related adverse events (see Risks).

  • Pre-existing health conditions: Adults with autoimmune disease, hyperthyroidism, or chronic liver disease are unlikely to derive net benefit and are at elevated risk.

  • Genetic polymorphisms: Robust pharmacogenetic data are sparse. Variants affecting cortisol metabolism (HSD11B1 — an enzyme that regenerates active cortisol in tissues; NR3C1 — the gene encoding the glucocorticoid receptor that cortisol acts on) and bile-acid transport (ABCB11/BSEP — the bile salt export pump that moves bile acids out of liver cells) are mechanistically plausible modifiers of efficacy and risk, respectively, but no clinical pharmacogenomic studies have been published.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Cholestatic / Hepatocellular Liver Injury

Since 2017, more than 35 case reports and a 2023 Indian case series have documented ashwagandha-associated drug-induced liver injury, typically presenting 2–12 weeks after starting a commercial extract with cholestatic (impaired bile flow from the liver) or mixed-pattern hepatocellular (liver-cell) injury, jaundice, and pruritus (intense itching of the skin). Most cases are mild-to-moderate and resolve within 1–4 months of discontinuation, but acute liver failure and acute-on-chronic liver failure with mortality have been reported, particularly in patients with pre-existing chronic liver disease. Mechanism is not established; withanolides themselves are suspected, although contaminant and idiosyncratic mechanisms cannot be ruled out. The NIH LiverTox monograph considers ashwagandha a recognized cause of clinically apparent drug-induced liver injury, and the converging multinational case literature plus the 2023 Danish national ban on ashwagandha-containing food supplements support a high-evidence categorization despite a low absolute incidence.

Magnitude: Estimated incidence under approximately 1 per 10,000 users in the published case literature, but underreporting is likely; case-fatality is high in users with underlying cirrhosis.

Medium 🟥 🟥

Thyroid Hormone Elevation

Ashwagandha consistently raises T3 and T4 in subclinical hypothyroid populations and has been linked to overt thyrotoxicosis (clinical syndrome from excessive thyroid hormone activity) in case reports of euthyroid users, including a documented case presenting with supraventricular tachycardia (a fast, abnormal heartbeat originating above the heart’s lower chambers). The mechanism is direct stimulation of thyroid hormone production. Risk is highest in adults with hyperthyroidism, autonomous thyroid nodules, Graves’ disease (an autoimmune disorder that drives the thyroid to overproduce hormone), or those already on thyroid hormone replacement.

Magnitude: Mean increases of approximately 20–40% in T3 and 15–20% in T4 in subclinical hypothyroidism trials; case reports of overt thyrotoxicosis number in the dozens rather than hundreds in the published literature.

Low 🟥

Gastrointestinal Side Effects

Mild, transient gastrointestinal symptoms — epigastric discomfort, nausea, loose stools, and decreased appetite — are the most commonly reported adverse events across clinical trials, occurring in roughly 5–10% of supplemented participants. Mechanisms include direct gastric mucosal irritation and possibly cholinergic effects. They typically resolve with dose reduction or discontinuation.

Magnitude: Approximately 5–10% incidence in pooled trials; severity is mild in nearly all reported cases.

Somnolence and Sedation

Daytime drowsiness, particularly with higher doses or daytime dosing, is reported in a minority of users. Mechanism is consistent with GABAergic activity. The effect can be desirable when ashwagandha is used to improve sleep but problematic when alertness is required.

Magnitude: Approximately 2–8% incidence in pooled trials; managed by moving the dose to evening.

Immune Activation in Autoimmune Disease ⚠️ Conflicted

Mechanistic and limited clinical data suggest ashwagandha can shift cytokine profiles toward Th1 (T-helper 1, the arm of the immune system that drives cell-mediated and pro-inflammatory responses) activity, with theoretical and case-report concern in patients with rheumatoid arthritis, multiple sclerosis, lupus, and Hashimoto’s thyroiditis. Empirical evidence is mixed — some autoimmune cohorts show benefit, others report flares.

Magnitude: Not quantified in available studies.

Pregnancy-Associated Risk (Theoretical and Animal Data)

Animal studies have reported abortifacient activity at high doses, and ashwagandha is contraindicated in pregnancy across Ayurvedic and modern guideline sources. No controlled human pregnancy trials exist, and post-marketing data are limited. Lactation data are also lacking.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term HPA-Axis Suppression

Sustained reduction of cortisol over months to years has not been studied in humans, and concerns about adrenal downregulation, blunted morning cortisol response, and possible withdrawal effects on cessation are mechanistic and not empirically established. Some practitioners cycle the supplement specifically to mitigate this theoretical risk.

Sex-Hormone Dysregulation in Women

Some commentators raise concern that androgenic effects observed in men could translate to unwanted symptoms (acne, hirsutism, menstrual change) in women, particularly those with PCOS (polycystic ovary syndrome, a hormonal disorder causing irregular periods and elevated androgens). Available trials in women are too small and short to support or refute the concern.

Hepatotoxicity Risk Stratification by Extract Type

Industry literature and some practitioner sources argue that risk of liver injury is concentrated in certain proprietary extracts, formulations containing high-withaferin-A leaf material, or contaminated batches, and is minimal for root-only extracts standardized to lower withaferin A. The case literature is too small and inconsistently reported to confirm or refute this stratification.

Risk-Modifying Factors

  • Pre-existing liver disease: Adults with cirrhosis, chronic hepatitis B or C, autoimmune hepatitis, or active alcohol-related liver disease appear at meaningfully higher risk of severe outcomes from ashwagandha-associated hepatotoxicity.

  • Thyroid status: Adults with hyperthyroidism, autonomous thyroid nodules, Graves’ disease, or those on stable thyroid hormone replacement are at elevated risk of thyroid hormone elevation and thyrotoxicosis.

  • Autoimmune disease: Adults with rheumatoid arthritis, multiple sclerosis, lupus, Hashimoto’s thyroiditis, or psoriasis face uncertain immunomodulatory effects with potential for flares.

  • Pregnancy and lactation: Pregnancy is a clear contraindication in traditional and modern guideline sources, with animal abortifacient signal and no controlled human data.

  • Genetic polymorphisms: No validated pharmacogenomic markers exist; mechanistically, variants in NAT2 (an enzyme that processes many drugs and toxins via acetylation), ABCB11/BSEP, and HLA (human leukocyte antigen, immune-system genes that influence individual susceptibility to drug reactions) alleles linked to herbal-induced liver injury are plausible candidates for stratifying hepatotoxicity risk but are not currently used clinically.

  • Sex differences: Hepatotoxicity case reports trend slightly female-predominant; thyroid-related events are more commonly reported in women, mirroring background prevalence of thyroid disease.

  • Age: Older adults are at higher absolute risk of liver injury, thyroid dysregulation, and drug interactions because of higher prevalence of underlying disease and polypharmacy, even though clinical trials enrolling older adults are limited.

  • Baseline biomarkers: Elevated baseline ALT (alanine aminotransferase, a liver enzyme released into blood when liver cells are injured) / AST (aspartate aminotransferase, a related liver and muscle enzyme), elevated TSH (in either direction relative to optimal), and elevated antinuclear antibodies signal populations who require additional caution and monitoring.

Key Interactions & Contraindications

  • Sedatives and CNS depressants (CNS = central nervous system; benzodiazepines such as alprazolam and lorazepam, “Z-drugs” such as zolpidem, opioids, alcohol): Caution. Additive sedation and respiratory depression risk are possible due to GABAergic activity. Avoid combination at high doses or separate by several hours.

  • Thyroid hormone replacement (levothyroxine, liothyronine, desiccated thyroid): Caution / monitor. Additive elevation of T3 and T4 with risk of iatrogenic thyrotoxicosis. Recheck TSH and free T4 every 6–8 weeks if combining.

  • Antihypertensives (ACE inhibitors — angiotensin-converting enzyme blockers that relax blood vessels, such as lisinopril; ARBs — angiotensin-receptor blockers that act on the same pathway, such as losartan; calcium-channel blockers; beta-blockers): Caution. Mild blood-pressure-lowering effect of ashwagandha may produce additive hypotension; monitor blood pressure when initiating.

  • Antidiabetic drugs (metformin, sulfonylureas, insulin, GLP-1 receptor agonists — drugs that mimic the gut-derived GLP-1 hormone to lower blood sugar and appetite, such as semaglutide): Caution / monitor. Possible additive glucose-lowering effect; monitor for hypoglycemia.

  • Immunosuppressants (tacrolimus, cyclosporine, mycophenolate, biologic DMARDs — disease-modifying anti-rheumatic drugs that target immune signaling): Caution to avoid. Theoretical immune activation may oppose immunosuppression and risk transplant rejection or autoimmune flare.

  • Sex-hormone modulating drugs (testosterone replacement, anti-androgens such as bicalutamide, 5-alpha-reductase inhibitors — drugs that block conversion of testosterone to its more potent form DHT, such as finasteride): Caution. Theoretical additive or opposing effects depending on direction; clinical data are limited.

  • Anticoagulants and antiplatelet drugs (warfarin, direct oral anticoagulants such as apixaban, aspirin, clopidogrel): Caution. Limited evidence of bleeding risk modification, but several case reports describe altered INR (international normalized ratio, a standardized measure of how quickly blood clots); monitor when combining.

  • Anesthetics and pre-surgical setting: Caution. Discontinue at least 2 weeks before elective surgery due to additive sedation, possible bleeding-time changes, and unclear effects on perioperative HPA-axis response.

  • Other adaptogens and herbs (Rhodiola rosea, Panax ginseng, holy basil, valerian, kava): Caution. Limited human data on combined adaptogen use; theoretical additive HPA-axis and sedative effects.

  • Hepatotoxic drugs (acetaminophen at high doses, methotrexate, isoniazid, statins, amoxicillin-clavulanate): Caution. Theoretical additive hepatotoxic risk; especially relevant in adults with elevated baseline liver enzymes.

  • Populations who should avoid this intervention: Pregnancy and lactation; active or chronic liver disease (Child–Pugh Class B or C, decompensated cirrhosis); hyperthyroidism, Graves’ disease, and autonomous thyroid nodules; active autoimmune disease (lupus, rheumatoid arthritis, multiple sclerosis flare, Hashimoto’s flare); solid-organ transplant recipients on immunosuppressants; patients within 14 days of elective surgery; children and adolescents under 18 (limited safety data); adults with active gastric or duodenal ulcers.

Risk Mitigation Strategies

  • Baseline and follow-up liver function testing: ALT, AST, ALP (alkaline phosphatase, a liver/biliary enzyme that rises in cholestatic patterns of injury), GGT (gamma-glutamyl transferase, a hepatobiliary enzyme used to confirm that an ALP rise is liver-derived), and total/direct bilirubin checked at baseline and at 8–12 weeks of use, with discontinuation if ALT or AST rises above 3 times the upper limit of normal or if jaundice or pruritus appear; this directly mitigates the risk of cholestatic and hepatocellular drug-induced liver injury.

  • Baseline and follow-up thyroid panel: TSH, free T3, and free T4 checked at baseline and at 8–12 weeks, with discontinuation or dose reduction if TSH falls below the lower limit of normal or free T4 rises above range; this mitigates the risk of iatrogenic thyrotoxicosis.

  • Avoidance in high-risk populations: Strict avoidance in pregnancy, lactation, chronic liver disease, hyperthyroidism, autoimmune disease flare, and within 14 days of elective surgery; this mitigates serious hepatic, thyroid, immune, and perioperative risks identified above.

  • Dose limitation: Capping daily total at 600 mg/day of standardized root extract for chronic use, with short-term increases up to 1,200 mg/day only in supervised clinical trial-like settings; this mitigates dose-related hepatic and thyroid risk and matches the dose ceiling at which most efficacy data plateau.

  • Cycling of chronic use: Several practitioners and clinical trial protocols use 8–12 weeks on followed by 2–4 weeks off, in part to mitigate theoretical long-term HPA-axis suppression and to provide a window in which liver function can normalize if subclinical injury has occurred.

  • Source verification: Selection of products with third-party testing (USP, NSF, ConsumerLab Approved) and standardized withanolide content, and avoidance of unverified mail-order or proprietary blends, mitigates the risk of contaminant- or adulterant-driven liver injury and ensures that delivered withanolide content matches label claims.

  • Avoiding leaf-heavy preparations in adults at hepatic risk: Some practitioners recommend root-only extracts (such as KSM-66, standardized to 5% withanolides from root) over leaf-containing or high-withaferin-A preparations in adults with elevated baseline ALT or family history of liver disease; this is a partial-evidence mitigation reflecting the suspicion that withaferin A or leaf-specific compounds drive hepatotoxicity.

  • Evening dosing: Taking the daily dose with the evening meal mitigates the risks of daytime somnolence and gastrointestinal upset and aligns with the preferred profile for sleep and cortisol-lowering effects.

  • Discontinuation at first sign of jaundice, pruritus, dark urine, or right-upper-quadrant pain: Immediate cessation and prompt medical evaluation for any cholestatic warning signs is the single most important consumer-level mitigation against severe hepatic injury.

Therapeutic Protocol

A standard protocol used in clinical trials and by integrative practitioners centers on standardized root extracts taken once or twice daily for 8–12 weeks, with periodic reassessment. Where competing approaches exist, the main alternatives are (a) root-only standardized extracts emphasized in conventional integrative protocols (KSM-66, 5% withanolides) and (b) higher-potency root + leaf extracts emphasized in some practitioner-led protocols (Sensoril, ≥10% withanolides; Shoden, 35% withanolides). Neither is established as superior; root-only is more conservative on hepatotoxicity, while leaf-containing extracts deliver more total withanolides per milligram.

  • Standard daily dose: 300–600 mg/day of root extract standardized to ≥5% withanolides (e.g., KSM-66), or 125–250 mg/day of higher-potency root + leaf extract (e.g., Sensoril). Doses above 1,200 mg/day are generally not used in clinical trials beyond short, supervised contexts.

  • Time of day: Most clinical trials and practitioner protocols favor evening dosing (often with dinner or 1–2 hours before bedtime) to align with the cortisol-lowering and sleep-supporting profile and to mitigate daytime somnolence. Peter Attia describes taking 600 mg in the evening for sleep; Andrew Huberman likewise describes late-day or evening dosing.

  • Single vs. split dosing: Either a single evening dose or twice-daily split dosing (morning and evening) is acceptable. Split dosing is sometimes preferred for stress reduction during the day; a single evening dose is preferred when the primary aim is sleep.

  • Half-life considerations: Withaferin A has a short estimated half-life (1–2 hours in animal data) but the broader withanolide mixture and downstream HPA effects appear to integrate over hours to days, making once-daily dosing pharmacodynamically reasonable despite the short pharmacokinetic half-life.

  • Duration: Most clinical trials run 8–12 weeks. Longer continuous use is common in practice but lacks controlled long-term safety data; practitioners frequently cycle (see Discontinuation & Cycling).

  • Form: Capsules of standardized extract are the most common and most studied form. Powdered raw root taken with milk and honey is the traditional Ayurvedic form; gummies and liquid tinctures are more recent commercial formats with less third-party testing.

  • Genetic considerations: No validated pharmacogenetic-guided dosing exists. Variants in HSD11B1, NR3C1, NAT2, and ABCB11 are mechanistically plausible modifiers but are not currently used clinically.

  • Sex-based considerations: Men with low baseline testosterone tend to receive testosterone-related benefits not seen in women. Women considering use for stress or sleep typically follow the same dosing as men. Pregnancy and breastfeeding are contraindications.

  • Age-related considerations: Older adults (over 65) should start at the lower end of the dose range (300 mg/day) given higher background prevalence of liver, thyroid, and polypharmacy concerns. No established geriatric protocol exists.

  • Baseline biomarkers: Elevated baseline ALT, AST, or TSH outside the optimal range, and active autoimmune disease, are reasons to defer or avoid initiation rather than adjust dose.

  • Pre-existing conditions: Adults with subclinical hypothyroidism, mild generalized anxiety, mild insomnia, or self-reported chronic stress are the most common users in clinical trial protocols and the populations with the clearest benefit-to-risk ratio.

Discontinuation & Cycling

  • Lifelong vs. short-term use: Ashwagandha is generally treated as a short-to-medium-term intervention (8–24 weeks) tied to a specific stress, sleep, or training period rather than as a lifelong daily supplement. Long-term continuous use beyond 12 months is common in practice but has no controlled safety data.

  • Withdrawal effects: No clearly characterized withdrawal syndrome is described in the human trial literature. Anecdotally, some users report rebound anxiety or sleep disruption when discontinuing abruptly after extended use, possibly reflecting return to baseline rather than physical dependence.

  • Tapering: Formal tapering is not required. A practical step-down (for example, halving the dose for one week before stopping) is sometimes used after long courses, primarily to make any rebound effects easier to interpret.

  • Cycling: Several integrative practitioners (including Andrew Huberman) describe cycling protocols — for example, 2 weeks on / 1–2 weeks off, or 8–12 weeks on / 2–4 weeks off — to reduce theoretical long-term HPA-axis suppression and provide a check-in point on liver and thyroid function. There is no controlled trial demonstrating that cycling is necessary or superior to continuous use for efficacy.

  • Stop criteria: Independent of any cycling schedule, immediate discontinuation is indicated for any sign of jaundice, dark urine, pruritus, right-upper-quadrant pain, palpitations, heat intolerance, weight loss, or unexplained tachycardia, pending medical evaluation.

Sourcing and Quality

  • Extract type: Standardized root extracts (e.g., KSM-66 at 5% withanolides) are the most studied; root + leaf extracts (e.g., Sensoril at ≥10% withanolides; Shoden at 35% withanolides) deliver more total withanolides per milligram and are favored by some practitioners for sleep but carry a less-characterized hepatotoxicity profile.

  • Withanolide content: ConsumerLab guidance is to look for root powder at ≥0.3% withanolides, root extract at ≥1.5% withanolides, and a daily dose providing at least 6 mg of withanolides; clinical trials typically deliver 10–30 mg of withanolides per day.

  • Third-party testing: Independent verification by USP, NSF, ConsumerLab, or equivalent is the most important quality marker, given that ConsumerLab has reported only 38% of tested ashwagandha products meet label claims. Approved seals indicate verified withanolide content and absence of contaminants such as heavy metals, pesticide residues, and microbial contamination.

  • Reputable brands: Among ConsumerLab-approved and widely studied options, brands carrying KSM-66 (e.g., Jarrow Formulas, Pure Encapsulations) and Sensoril (e.g., Solgar, Nutragenesis) are the most commonly cited in clinical trials. Life Extension Optimized Ashwagandha and Pure Encapsulations Ashwagandha have appeared in ConsumerLab Approved lists in past testing rounds.

  • Avoiding contamination: Heavy metal contamination (lead, arsenic) has been reported in non-tested ashwagandha products from informal supply chains; third-party testing is the most direct mitigation.

  • Form factor: Capsules of standardized extract are most consistent. Powdered raw root provides the traditional Ayurvedic delivery but with high batch-to-batch variability. Gummies and tinctures often deliver substantially less than label claim and are not typically used in clinical research.

  • Storage and shelf life: Withanolides are sensitive to heat and light; storage in a cool, dry place in opaque packaging is standard.

  • Label transparency: Products that disclose the specific standardized extract used (e.g., “KSM-66”), the withanolide percentage, the plant part (root only vs. root + leaf), and a third-party testing seal are preferable to unbranded “ashwagandha extract” listings without standardization.

Practical Considerations

  • Time to effect: Subjective stress and anxiety effects are typically reported within 2–4 weeks; sleep improvements within 4–8 weeks; cortisol, thyroid, testosterone, and VO₂max changes generally measured at 8–12 weeks. Trials shorter than 8 weeks frequently fail to show full effect sizes.

  • Common pitfalls: Use of unverified products with negligible withanolide content (the most common issue in ConsumerLab testing); daytime dosing producing somnolence; combining with sedatives, thyroid medications, or immunosuppressants without monitoring; continued use despite unexplained fatigue, jaundice, or palpitations; assumption that “natural” implies absence of liver or thyroid risk; expecting immediate effects within days rather than weeks.

  • Regulatory status: In the United States, ashwagandha is sold as a dietary supplement under DSHEA (Dietary Supplement Health and Education Act), without pre-market efficacy or safety review. The European Union permits it as a food supplement in most member states, but Denmark imposed a national ban on ashwagandha-containing food supplements in 2023 citing thyroid and reproductive concerns. Several other regulators have issued advisories on hepatotoxicity. It is not approved as a drug in the United States, EU, UK, or Canada.

  • Cost and accessibility: Standardized root-extract capsules typically cost USD 10–40 per month at clinically relevant doses, well within reach of the target audience. ConsumerLab found that the cost to obtain 6 mg of withanolides ranged from approximately 6 cents to USD 1.77 across tested products, with price not predicting quality. Worldwide availability is broad except in jurisdictions with regulatory bans.

Interaction with Foundational Habits

  • Sleep: Direct, generally positive interaction. Evening dosing of 300–600 mg root extract improves PSQI scores, reduces sleep-onset latency, and increases total sleep time, especially in adults with insomnia. The mechanism combines GABAergic activity and reduced bedtime cortisol. Practical implication: dose with the evening meal or within 1–2 hours of bedtime; avoid morning-only dosing if sleep is the primary target.

  • Nutrition: Indirect, mostly neutral interaction. No specific dietary pattern is required, and ashwagandha does not reliably deplete major nutrients. Traditional Ayurvedic preparation pairs powdered root with milk, ghee, or honey; some practitioners recommend taking it with food to reduce gastrointestinal side effects. Excess saturated-fat or alcohol-heavy diets that already burden the liver may compound hepatotoxicity risk.

  • Exercise: Direct, potentiating interaction. In resistance-trained men, 600 mg/day root extract has been associated with modest gains in 1-rep-max strength, lean mass, and reductions in creatine kinase post-exercise; in athletes, modest VO₂max gains. Mechanism includes reduced exercise cortisol and improved recovery. Practical implication: dose timing relative to training has not been shown to materially change outcomes, so evening dosing for sleep and recovery is standard rather than around-the-workout dosing.

  • Stress management: Direct, potentiating interaction. Effects on perceived stress and cortisol are additive with established stress-management practices (meditation, breathwork, cognitive-behavioral approaches, time outdoors). Mechanism overlaps via HPA-axis modulation. Practical implication: ashwagandha is most useful as a complement to behavioral stress management in chronically stressed adults, not as a substitute.

Monitoring Protocol & Defining Success

Baseline testing establishes hepatic, thyroid, and (where relevant) gonadal status before initiation, and supports decisions about whether to start, defer, or avoid ashwagandha given individual risk. Ongoing monitoring at 8–12 weeks captures both efficacy signals and the most clinically relevant adverse-event signals (liver enzymes, thyroid hormones), with continued cadence every 6–12 months for chronic users.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
ALT <19 U/L (women), <30 U/L (men) Detects ashwagandha-associated hepatocellular injury early Alanine aminotransferase. Conventional reference: <40 U/L; fasting not required; rise above 3× upper limit of normal warrants discontinuation
AST <25 U/L Detects hepatocellular injury and adds specificity in muscle-active populations Aspartate aminotransferase. Conventional reference: <40 U/L; interpret jointly with ALT and creatine kinase
ALP <100 U/L Detects cholestatic-pattern injury, the most common pattern of ashwagandha hepatotoxicity Alkaline phosphatase. Conventional reference: 30–130 U/L; interpret with GGT and bilirubin
GGT <30 U/L Confirms hepatobiliary origin of ALP elevation; sensitive to alcohol and drug-induced cholestasis Gamma-glutamyl transferase. Optimal range tighter than conventional; combine with ALP
Total and direct bilirubin Total <1.0 mg/dL; direct <0.3 mg/dL Detects clinically significant cholestasis; jaundice mandates immediate discontinuation Conventional reference: total up to 1.2 mg/dL
TSH 0.5–2.0 mIU/L Detects ashwagandha-induced thyroid hormone elevation Thyroid-stimulating hormone. Conventional reference: 0.4–4.5 mIU/L; pair with free T4
Free T4 1.0–1.5 ng/dL Confirms direction of thyroid effect; rise above range warrants discontinuation Conventional reference: 0.8–1.8 ng/dL
Free T3 3.0–3.5 pg/mL Most sensitive marker of ashwagandha-induced thyroid hormone elevation Conventional reference: 2.3–4.2 pg/mL
Total testosterone (men) 600–900 ng/dL Tracks the modest testosterone-raising signal in men using ashwagandha for hypogonadal symptoms or training support Morning fasting draw; pair with sex hormone-binding globulin (SHBG, the carrier protein for testosterone) and free testosterone
SHBG 20–40 nmol/L (men), 30–60 nmol/L (women) Helps interpret total testosterone changes Some practitioners report SHBG decreases with Sensoril
Fasting glucose / HbA1c <90 mg/dL / <5.4% Tracks possible additive glucose-lowering with antidiabetic drugs Conventional reference for HbA1c: <5.7%; relevant if combining with metformin or insulin
Perceived Stress Scale (PSS-10) <13 (low); track change Quantitative outcome marker for stress reduction Self-administered; useful for measuring response

Baseline labs (liver and thyroid panels above) should be drawn before starting any course longer than 4 weeks, and repeated at 8–12 weeks of continuous use, then every 6–12 months for chronic users. PSS-10 and any sleep-quality instrument (PSQI, Insomnia Severity Index) can be self-administered at baseline and at 4, 8, and 12 weeks to track subjective response.

Qualitative markers worth tracking subjectively:

  • Perceived daytime stress and ease of recovery from acute stressors
  • Sleep onset latency and number of nighttime awakenings
  • Morning energy and clarity on waking
  • Exercise recovery (delayed-onset soreness, perceived effort during baseline workouts)
  • Mood stability and irritability
  • Libido (men)
  • Heat tolerance, palpitations, unintentional weight loss (warning signs of thyroid hormone elevation)
  • Right-upper-quadrant discomfort, dark urine, pruritus, jaundice (warning signs of liver injury)

Emerging Research

  • Ashwagandha for Nighttime Waking (NCT07151261): A 54-participant randomized placebo-controlled trial measuring change in mean Wake After Sleep Onset (WASO) at 4 weeks, addressing a specific weakness of prior trials in which WASO was not a primary endpoint. Active not recruiting as of late 2025; could clarify whether ashwagandha’s sleep benefit extends specifically to mid-night awakenings, the most common complaint in older adults.

  • Effects of Ashwagandha Extract on Stress Levels (NCT06793891): A 60-participant trial comparing root-only and root + leaf preparations versus placebo, with cortisol awakening response and a proprietary stress scale as primary endpoints. Recruiting; one of the first trials directly contrasting root-only and root + leaf preparations on a stress endpoint.

  • Proprietary Aqueous Ashwagandha Root Extract vs. KSM-66 vs. Placebo (NCT06714942): A 51-participant three-arm trial measuring serum cortisol over 8 weeks. Recruiting; head-to-head extract comparisons of this kind are rare and would address ongoing questions about whether published efficacy generalizes across proprietary preparations.

  • Effectiveness of a Proprietary Ashwagandha Extract on Menopausal Symptoms (NCT07210229): A 90-participant three-arm trial in menopausal women using ashwagandha root and ashwagandha root + leaf preparations against placebo, with multiple validated menopause symptom scales as endpoints. Could move menopause-symptom evidence from Speculative toward Low or Medium if positive.

  • KSM-66 Ashwagandha for Skin and Hair Health (NCT07215689): A 50-participant placebo-controlled trial measuring trans-epidermal water loss and other skin-quality endpoints over 8–12 weeks. Recruiting; an early test of marketing claims around skin and hair that have so far rested on mechanism rather than human outcomes.

  • Long-term safety surveillance: Future research areas that could weaken the case for ashwagandha center on prospective hepatotoxicity surveillance and on better characterization of thyroid-related adverse events. Philips et al.’s 2023 Hepatology Communications case series and the LiverTox monograph are likely to drive this work.

  • Pharmacogenomics of herbal hepatotoxicity: Future research could clarify whether HLA, NAT2, and BSEP variants stratify ashwagandha hepatotoxicity risk, by analogy with established pharmacogenomic predictors of drug-induced liver injury for amoxicillin-clavulanate and flucloxacillin.

  • Longevity-relevant endpoints: No published trial has assessed ashwagandha against frailty, deficit-accumulation indices, or all-cause mortality. Pragmatic trials with these endpoints would substantially strengthen or weaken the longevity-framed case.

Conclusion

Ashwagandha is an Ayurvedic root extract with a long traditional record and an expanding modern clinical literature. The strongest signal is short-term reduction of perceived stress, anxiety, and serum cortisol in stressed adults, supported by multiple randomized controlled trials and pooled meta-analyses, although heterogeneity is high and certainty of evidence has been rated low by independent reviewers. Smaller bodies of evidence support modest benefits for sleep quality in adults with insomnia, aerobic capacity in athletes, strength and recovery in resistance-trained men, testosterone in men with low baseline values, and thyroid hormone normalization in subclinical hypothyroidism. Claims of broad neuroprotection, menopausal symptom relief, and longevity benefits remain largely mechanistic or based on small pilot trials.

On the risk side, post-marketing case reports establish ashwagandha as a recognized cause of liver injury, occasionally severe in adults with pre-existing chronic liver disease, alongside well-characterized thyroid hormone elevation and a lower-grade signal of immune activation in autoimmune disease. The evidence base is shaped by extensive industry funding and reliance on a small number of proprietary extracts, which has contributed to inconsistent translation between products. The intervention is most coherent as a short-to-medium-term tool for chronic stress, anxiety, and sleep difficulty in healthy adults, with explicit avoidance in pregnancy, hyperthyroidism, autoimmune flare, and chronic liver disease, and with baseline and follow-up monitoring of hepatic and thyroid function.

Top - Benefits - Risks - Protocol